#EAU20 Virtual Congress

EAU
Europe/Paris GMT+2

Description

Game changing session 2

Game changing session

 

Sat 18 July

08:30 - 09:05

Location:Virtual room 1Chairs: J. Palou, Barcelona (ES)

K.A.O. Tikkinen, Helsinki (FI)

 

08:30 - 08:45

Recurrence risk in patients with High Grade Non-Muscle Invasive Bladder Carcinoma in the Randomised Phase III Clinical Trial ‘NIMBUS’ stratified for EORTC and CUETO risk categories. A contemporary trend to less recurrences?

08:30 - 08:38

Presenter

M-O. Grimm, Jena (DE)

08:38 - 08:45

Discussant

P. Black, Vancouver (CA)

08:45 - 09:00

Results from the phase III study of nadofaregene firadenovec: Safety and efficacy in patients (pts) with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

08:45 - 08:53

Presenter

N. Shore, Myrtle Beach (US)

08:53 - 09:00

Discussant

J.A. Witjes, Nijmegen (NL)

09:00 - 09:05

Discussion, questions and answers

J. Palou, Barcelona (ES)

K.A.O. Tikkinen, Helsinki (FI)

 

Challenges across the spectrum of bladder cancer

Plenary session 03

 

Sat 18 July

09:05 - 11:25

Location:Virtual room 2Chairs: J.W.F. Catto, Sheffield (GB)

M. Rouprêt, Paris (FR)

A. Stenzl, Tübingen (DE)

 

Learning objectives

Clinical decision making for non muscle-invasive bladder cancer and new tools for adjuvant treatment for these tumours take a large part of this session. Furthermore an optimisation in the selection of elderly patients with advanced bladder cancer for surgical vs. conservative treatment will be presented. One part of the session deals with personalised treatment and its underlying genetic testing in bladder cancer.

 

09:05 - 09:15

Definition of very high-risk and refractory NMIBC

M. Babjuk, Prague (CZ)

09:15 - 09:45

Early cystectomy in high-risk NMIBC: A standard?

09:15 - 09:25

Pro

S. Shariat, Vienna (AT)

09:25 - 09:35

Con

J. Palou, Barcelona (ES)

09:35 - 09:45

Discussion

Moderators :

J.W.F. Catto, Sheffield (GB)

M. Rouprêt, Paris (FR)

A. Stenzl, Tübingen (DE)

Panel :

J. Palou, Barcelona (ES)

S. Shariat, Vienna (AT)

09:45 - 10:00

Immunotherapy and beyond: New options for NMIBC

P. Black, Vancouver (CA)

10:00 - 10:15

Urinary markers in low-grade NMIBC: Ready to stop cystoscopies?

J.A. Witjes, Nijmegen (NL)

10:15 - 10:30

Frailty and cognitive assessment in patients diagnosed with MIBC

G. Pignot, Marseille (FR)

10:30 - 10:45

Treatment options for elderly patients with muscle-invasive bladder cancer

M.J. Ribal Caparros, Barcelona (ES)

10:45 - 11:00

Different bladder cancer genotypes: New treatment options

R. Seiler, Bern (CH)

11:00 - 11:15

The future of personalised treatment: Test the tumour for a response

M. Shen, New York (US)

11:15 - 11:25

Discussion, questions and answers

J.W.F. Catto, Sheffield (GB)

M. Rouprêt, Paris (FR)

A. Stenzl, Tübingen (DE)

 

Five things I wish I would have known earlier in my career: Lessons from the mentors

Thematic session 05

 

Sat 18 July

11:25 - 13:00

Location:Virtual room 1Chairs: F. Montorsi, Milan (IT)

J. Palou, Barcelona (ES)

 

Learning objectives

During a long and successful career, many decisions that are taken on the basis of the evidence available at that specific time have subsequently proven incorrect.

 

Three recognised Mentors in Urology: Peter Carroll for Prostate Cancer, Inderbir Gill for Kidney Cancer and Mark Soloway for Bladder Cancer will scrutinize their own extraordinary personal experience achieved over many years to identify the mistakes done, how they were able to manage them and how they subsequently changed their practice.

 

At the end of each talk, another top expert in the same field will summarize for the audience what the contemporary guidelines are saying about the management of that disease.

 

Delegates will learn from the outstanding experience of these giants in urology and their counterparts. Learning from mistakes is a phenomenally important part of the professional growth of each urologist.

 

11:25 - 11:55

Bladder cancer

11:25 - 11:45

Speaker

M.S. Soloway, Miami (US)

11:45 - 11:55

Discussant

J.W.F. Catto, Sheffield (GB)

11:55 - 12:25

Kidney cancer

11:55 - 12:15

Speaker

I.S. Gill, Los Angeles (US)

12:15 - 12:25

Discussant

C.K. Bensalah, Rennes (FR)

12:25 - 12:55

Prostate cancer

12:25 - 12:45

Speaker

P. Carroll, San Francisco (US)

12:45 - 12:55

Discussant

A. Briganti, Milan (IT)

12:55 - 13:00

Discussion, questions and answers

F. Montorsi, Milan (IT)

J. Palou, Barcelona (ES)

 

Game changing session 3

Game changing session

 

Sat 18 July

13:00 - 13:20

Location:Virtual room 2Chairs: C.R. Chapple, Sheffield (GB)

H. Van Poppel, Leuven (BE)

 

13:08 - 13:15

Discussant

S. Joniau, Leuven (BE)

13:00 - 13:15

The real effect of prostate cancer treatment: EUPROMS study first patient driven quality of life study ever

13:00 - 13:08

Presenter

A. Deschamps, Antwerpen (BE)

13:15 - 13:20

Discussion, questions and answers

C.R. Chapple, Sheffield (GB)

H. Van Poppel, Leuven (BE)

 

Bladder dysfunction, storage symptoms and benign prostatic disease

Plenary session 04

 

Sat 18 July

13:20 - 15:00

Location:Virtual room 1Chairs: J-N.L. Cornu, Rouen (FR)

C. Gratzke, Freiburg (DE)

 

Learning objectives

This plenary session on male LUTS will cover the topic of bladder dysfunction especially in the context of concomitant benign prostatic obstruction. Leaders in the field will comprehensively discuss up-to-date medical and surgical solutions, recent advances in the therapies of male LUTS and current key pathophysiological concepts underlying male LUTS.

 

13:20 - 13:30

Basic neurological workup in a male LUTS patient: Keypoints for daily clinical practice

L. Campeau, Montreal (CA)

13:30 - 13:55

Non-neurogenic OAB in a 60yr man with 60g prostate: First-line medical prescription

13:30 - 13:35

Choose anticholinergics

C. De Nunzio, Rome (IT)

13:35 - 13:40

Choose a Beta-3 agonist

J-N.L. Cornu, Rouen (FR)

13:40 - 13:45

Choose alpha blockers

S.A. Arlandis, Valencia (ES)

13:45 - 13:50

Role of combination therapy

S. Madersbacher, Vienna (AT)

13:50 - 13:55

Questions and answers

J-N.L. Cornu, Rouen (FR)

C. Gratzke, Freiburg (DE)

13:55 - 14:20

Non-neurogenic OAB and proven obstuction, drugs don't work

13:55 - 14:00

Preference for resection

M. Speakman, Taunton (GB)

14:00 - 14:05

Preference for vaporisation

M. Gacci, Florence (IT)

14:05 - 14:10

Preference for enucleation

T.R.W. Herrmann, Frauenfeld (CH)

14:10 - 14:15

Preference for aquablation

A. Miernik, Freiburg (DE)

14:15 - 14:20

Questions and answers

J-N.L. Cornu, Rouen (FR)

C. Gratzke, Freiburg (DE)

14:20 - 14:30

Persistence of OAB symptoms after prostate surgery, despite good de-obstruction

M. Rieken, Vienna (AT)

14:30 - 15:00

Minimally-invasive options for day case surgery

14:30 - 14:35

Urolift

N. Barber, Camberley (GB)

14:35 - 14:40

TIND

F. Porpiglia, Turin (IT)

14:40 - 14:45

Rezum therapy

R.G. Hindley, Hook (GB)

14:45 - 14:50

Day case Greenlight laser vaporisation

B. Pradere, Toulouse (FR)

14:50 - 14:55

Prostate embolisation

D. Abt, St. Gallen (CH)

14:55 - 15:00

Questions and answers

J-N.L. Cornu, Rouen (FR)

C. Gratzke, Freiburg (DE)

 

Urinary reconstruction in (neuro)urology

Thematic session 06

 

Sat 18 July

16:00 - 16:30

Location:Virtual room 1Chairs: C.R. Chapple, Sheffield (GB)

J.P.F.A. Heesakkers, Nijmegen (NL)

 

Learning objectives

After the introduction of botulinum toxin A in the armamentarium of neurogenic bladder dysfunction, other more complex treatment options have been very much ignored. However Botulinum toxin does not work in every case. Advances in sacral neuromodulation have occurred and may prove useful for neurogenic patients. Urinary diversion may be a realistic option in complex cases, and urologists need to familiarize themselves with other neurological problems in addition to MS or SCI. Parkinson’s disease is a good example of a disease with multiple urological problems urologists that should be aware of.

 

16:00 - 16:30

Debate What happens if Botox does not work in MS anymore?

16:00 - 16:05

Case presentation

M. Tutolo, Milan (IT)

16:05 - 16:15

Go for surgery

B. Peyronnet, Rennes (FR)

16:15 - 16:25

Stay conservative

G. Del Popolo, Florence (IT)

16:25 - 16:30

Discussion, questions and answers

C.R. Chapple, Sheffield (GB)

J.P.F.A. Heesakkers, Nijmegen (NL)

 

Salvage LND prostate cancer

Thematic session 08

 

Sat 18 July

18:10 - 19:40

Location:Virtual room 2Chairs: C.H. Bangma, Rotterdam (NL)

F. Montorsi, Milan (IT)

 

Learning objectives

Here we review the biology and treatment for advanced local and distant metastatic prostate cancer. We consider treatment options and discuss which is better and for whom.

 

18:10 - 18:25

Does early diagnosis help the patient?

A. Briganti, Milan (IT)

18:25 - 19:00

Primary treatment of pelvic lymph node metastatic prostate cancer

18:25 - 18:35

Surgery only

K. Touijer, New York (US)

18:35 - 18:45

Radiation only

N. Van As, London (GB)

18:45 - 18:55

Systemic only

R.J.A. Van Moorselaar, Amsterdam (NL)

18:55 - 19:00

Discussion, questions and answers

C.H. Bangma, Rotterdam (NL)

F. Montorsi, Milan (IT)

19:00 - 19:25

Treatment of recurrent lymph node metastatic PCa

19:00 - 19:10

Surgery is the best option

S. Joniau, Leuven (BE)

19:10 - 19:20

Radiation is the best option

P. Ost, Ghent (BE)

19:20 - 19:25

Discussion, questions and answers

C.H. Bangma, Rotterdam (NL)

F. Montorsi, Milan (IT)

19:25 - 19:40

Treatment of polymetastatic hormone sensitive prostate cancer

C. Sweeney, Boston (US)

 

Immunotherapy and beyond

Thematic session 07

 

Sat 18 July

17:00 - 18:10

Location:Virtual room 1Chairs: S. Gillessen Sommer, Bellinzona (CH)

R.J. Van Soest, Rotterdam (NL)

 

Learning objectives

This session will provide an overview of the current challenges and obstacles in the treatment of urothelial cancer and renal cell carcinoma in view of recently approved agents and combinations including immunotherapy, targeted agents and combinations.

 

17:00 - 17:05

Introduction

17:05 - 17:50

Perioperative therapy for urothelial cancer

17:05 - 17:15

Chemotherapy remains standard of care

G. Niegisch, Düsseldorf (DE)

17:15 - 17:25

PD-1/PD-L1 Inhibitors are replacing perioperative chemotherapy

J.L. Boormans, Rotterdam (NL)

17:25 - 17:35

Should we sequence all urothelial cancer patients?

S. Shariat, Vienna (AT)

17:35 - 17:45

Novel urothelial cancer treatment beyond PD-1/PD-L1 inhibition

Y. Loriot, Villejuif (FR)

17:45 - 17:50

Discussion, questions and answers

17:50 - 18:15

Immunotherapy combinations for intermediate-poor risk mRCC

17:50 - 18:00

IO + TKI

A.S. Merseburger, Lübeck (DE)

18:00 - 18:10

IO + IO

M. Schmidinger, Vienna (AT)

J. Palou, K.A.O. Tikkinen, J.W.F. Catto, M. Rouprêt, A. Stenzl, F. Montorsi, C.R. Chapple, H. Van Poppel, J-N.L. Cornu, C. Gratzke, J.P.F.A. Heesakkers, J.O.R. Sønksen, S. Gillessen Sommer, R.J. Van Soest, C.H. Bangma, P. Albers, Z. Culig

Recurrence risk in patients with High Grade Non-Muscle Invasive Bladder Carcinoma in the Randomised Phase III Clinical Trial ‘NIMBUS’ stratified for EORTC and CUETO risk categories. A contemporary trend to less recurrences?, Definition of very high-risk and refractory NMIBC, Bladder cancer, The real effect of prostate cancer treatment: EUPROMS study first patient driven quality of life study ever, Basic neurological workup in a male LUTS patient: Keypoints for daily clinical practice, What happens if Botox does not work in MS anymore?, 3rd prize - non-oncology 640 Increased stromal components and prostatic fibrosis via altering the CYP19/Estrogen/GPER signaling in the early progression of BPH tissues of men ≤ 50 years old, Perioperative therapy for urothelial cancer, Does early diagnosis help the patient?, 2nd prize - oncology 925 Late toxicity and quality of life from GETUG-AFU 22 study: A randomised phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy

Inglês

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES
 

Speakers

M-O. Grimm, N. Shore, M. Babjuk, S. Shariat, J. Palou, P. Black, J.A. Witjes, G. Pignot, M.J. Ribal Caparros, R. Seiler, M. Shen, M.S. Soloway, I.S. Gill, P. Carroll, A. Deschamps, L. Campeau, C. De Nunzio, J-N.L. Cornu, S.A. Arlandis, S. Madersbacher, M. Speakman, M. Gacci, T.R.W. Herrmann, A. Miernik, M. Rieken, N. Barber, F. Porpiglia, R.G. Hindley, B. Pradere, D. Abt, M. Tutolo, B. Peyronnet, G. Del Popolo, Y. Yang, Y. Akiyama, H. Ito, G. Niegisch, J.L. Boormans, S. Shariat, Y. Loriot, A.S. Merseburger, M. Schmidinger, A. Briganti, K. Touijer, N. Van As, R.J.A. Van Moorselaar, S. Joniau, P. Ost, C. Sweeney, P. Sargos, A. Gao

 

Link to the Event

Banner to the Event

#EAU20 Virtual Congress
 
 
 

Download the Agenda

Search for our next event. See you soon!

Subscribe to get news on all upcoming events

DocMeeetings

Social Media

  • Twitter DocMeetings
  • Instagram DocMeetings
  • Facebook ícone social
  • LinkedIn ícone social

contact us

Adress

Sao Paulo, SP - Brazil

© 2020 by Docmeetings - A DocMeetings.com Company
Site Managed by:
QUALITY Soluções Web
1996-2021 "25 years inspiring technology"